Multidonor FMT capsules improve symptoms and decrease fecal calprotectin in ulcerative colitis patients while treated – an open-label pilot study

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.
   PubMed Web of Science ®Google Scholar
• Park JH, Peyrin-Biroulet L, Eisenhut M, et al. IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16:416–426.
   PubMed Web of Science ®Google Scholar
• Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1–10.
   PubMed Web of Science ®Google Scholar
• Schulberg J, De Cruz P. Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease. Intern Med J. 2016;46:266–273.
   PubMed Web of Science ®Google Scholar
• Rajilic-Stojanovic M, Shanahan F, Guarner F, et al. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis. 2013;19:481–488.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu ZZ, He Y, et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018;3:00188–17.
   Web of Science ®Google Scholar
• Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–1283.
   PubMed Web of Science ®Google Scholar
• Lopez-Siles M, Enrich-Capo N, Aldeguer X, et al. Alterations in the abundance and co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the colonic mucosa of inflammatory bowel disease subjects. Front Cell Infect Microbiol. 2018;8:281.
   PubMed Web of Science ®Google Scholar
• Silva JPB, Navegantes-Lima KC, Oliveira ALB d, et al. Protective mechanisms of butyrate on inflammatory bowel disease. Curr Pharm Des. 2018;24:4154–4166.
   Web of Science ®Google Scholar
• Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2018;4:293–305.
   Web of Science ®Google Scholar
• Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318:1985–1993.
   PubMed Web of Science ®Google Scholar
• Ianiro G, Maida M, Burisch J, et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: a systematic review and meta-analysis. United European Gastroenterol J. 2018;6:1232–1244.
   PubMed Web of Science ®Google Scholar
• Allegretti JR, Fischer M, Sagi SV, et al. Fecal microbiota transplantation capsules with targeted colonic versus gastric delivery in recurrent clostridium difficile infection: a comparative cohort analysis of high and lose dose. Digest Dis Sci. 2018. DOI:10.1007/s10620-018-5396-6
   Web of Science ®Google Scholar
• Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–109.e6.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218–1228.
   PubMed Web of Science ®Google Scholar
• Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110–118.e4.
   PubMed Web of Science ®Google Scholar
• Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis. A randomized clinical trial. JAMA. 2019;321:156–164.
   PubMed Web of Science ®Google Scholar
• Costello SP, Soo W, Bryant RV, et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46:213–224.
   PubMed Web of Science ®Google Scholar
• Fang H, Fu L, Wang J. Protocol for fecal microbiota transplantation in inflammatory bowel disease: a systematic review and meta-analysis. BioMed Res Int. 2018;2018:1–11.
   Web of Science ®Google Scholar
• Imdad A, Nicholson MR, Tanner-Smith EE, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2018;(11):CD012774.
   PubMedGoogle Scholar
• Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hospital Infect. 2016;92:117–127.
   PubMed Web of Science ®Google Scholar
• Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised. Double-blind placebo-controlled study. Gut. 2018;67:2107–2115.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569–580.
   PubMed Web of Science ®Google Scholar
• Chehri M, Christensen AH, Halkjaer SI, et al. Case series of successful treatment with fecal microbiota transplant (FMT) oral capsules mixed from multiple donors even in patients previously treated with FMT enemas for recurrent Clostridium difficile infection. Medicine. 2018;97:e11706.
   PubMed Web of Science ®Google Scholar
• Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29–32.
   PubMed Web of Science ®Google Scholar
• Cheung WY, Garratt AM, Russell IT, et al. The UK IBDQ-a British version of the inflammatory bowel disease questionnaire. development and validation. J Clin Epidemiol. 2000;53:297–306.
   PubMed Web of Science ®Google Scholar
• Imparato V, Hansen V, Santos SS, et al. Gasification biochar has limited effects on functional and structural diversity of soil microbial communities in a temperate agroecosystem. Soil Biol Biochem. 2016;99:128–136.
   Web of Science ®Google Scholar
• Callahan BJ, McMurdie PJ, Holmes SP. Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. Isme J. 2017;11:2639–2643.
   PubMed Web of Science ®Google Scholar
• Lagkouvardos I, Fischer S, Kumar N, et al. Rhea: a transparent and modular R pipeline for microbial profiling based on 16S rRNA gene amplicons. PeerJ. 2017;5:e2836.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Methodol. 1995;57:289–300.
   Web of Science ®Google Scholar
• Jairath V, Zou GY, Parker CE, et al. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017;(9):CD011572.
   PubMed Web of Science ®Google Scholar
• Lau E, Carvalho D, Pina-Vaz C, et al. Beyond gut microbiota: understanding obesity and type 2 diabetes. Hormones (Athens, Greece). 2015;14:358–369.
   PubMedGoogle Scholar
• Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. Wjg. 2015;21:711597–711608.
   Web of Science ®Google Scholar
• Cenit MC, Sanz Y, Codoner-Franch P. Influence of gut microbiota on neuropsychiatric disorders. Wjg. 2017;23:5486–5498.
   PubMed Web of Science ®Google Scholar
• Chen J, Chia N, Kalari KR, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao F, Wang Y, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5:14.
   PubMed Web of Science ®Google Scholar